From anemia to hemochromatosis. How to save the heart?

DOI: https://doi.org/10.29296/25877305-2022-03-11
Issue: 
3
Year: 
2022

Associate Professor Z. Mikhailova, MD; A. Saidov City clinical hospital Thirty-Eighth, Nizhny
Novgorod

The paper presents the clinical case of the patient with chronic myelomonocytic leukemia, development of secondary post-transfusion hemochromatosis with the possible cardiac involvement and chronic heart failure, pulmonary hypertension, as well as deep vein occlusive thrombosis of the left lower extremity and consequences of ischemic stroke as complication of thrombocytosis.
Keywords: 
anemia
red blood cell suspension transfusions
hemochromatosis
heart
iron chelators
thrombocytosis
thrombosis

References: 
  1. Bolezni peregruzki zhelezom (gemohromatozy): rukovodstvo dlja vrachej. Pod red. A.G. Rumjantseva, Ju.N. Tokareva. M.: ID Medpraktika-M, 2004; 328 s.
  2. Ivashkin V.T. Gastroenterologija. Pod red. V.T. Ivashkina, T.L. Lapinoj. M.: GEOTAR-Media, 2008; 704 s.
  3. European Association For The Study Of The Liver. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol. 2010; 53 (1): 3–22. DOI: 10.1016/j.jhep.2010.03.001
  4. Bacon B.R., Adams P.C., Kowdley K.V. et al. American Association for the Study of Liver Diseases. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011; 54 (1): 328–43. DOI: 10.1002/hep.24330
  5. Feoktistova E.V. i dr. Sostojanie serdtsa pri sindrome peregruzke zhelezom. Prakticheskaja meditsina. 2013; 6 (75): 59–60.
  6. Peregruzka zhelezom: diagnostika i lechenie. Natsional'nye klinicheskie rekomendatsii, 2018. 14 s.
  7. Kowdley K.V., Brown K.E., Ahn J. et al. ACG Clinical Guideline: Hereditary Hemochromatosis. Am J Gastroenterol. 2019; 114 (8): 1202–18. DOI: 10.14309/ajg.0000000000000315
  8. Kardiologija. Natsional'noe rukovodstvo. Pod red. E.V. Shljahto. 2-e izd., pererab. i dop. M.: GEOTAR-Media, 2019; 800 s.
  9. Skvortsov V.V., Gorbach A.N. Porazhenija pecheni pri gemohromatoze: klinicheskie projavlenija i diagnostika. Effektivnaja farmakoterapija. 2020; 16 (1): 74–8. DOI: 10.33978/2307-3586-2020-16-1-74-78
  10. Hamilton J.P.A. Secondary Iron Overload (Secondary Hemochromatosis). Johns Hopkins University School of Medicine Last full review/revision Sep 2020. Content last modified Sep 2020.
  11. Sisakian H.S., Asatryan B.A., Nanapetyan H.M. Dilated cardiomyopathy: evolution of pathogenesis concepts and potential for new therapies. New Armenian Medical Journal. 2015; 9 (1): 4–18.
  12. Hronicheskaja serdechnaja nedostatochnost'. Klinicheskie rekomendatsii 2020. Rossijskij kardiologicheskij zhurnal. 2020; 25 (11): 4083. DOI: 10.15829/1560-4071-2020-4083
  13. Mehtiev S.N., Mehtieva O.A. Sindrom peregruzki zhelezom pri hronicheskih zabolevanijah pecheni: fokus na nealkogol'nuju zhirovuju bolezn' pecheni. Lechaschij vrach. 2017; 12: 60–7.
  14. Isma’eel H., Cappellini M.D., Taher A. Chronic transfusion, iron overload and cardiac dysfunction: a multi-dimensional perspective. Br J Cardiol. 2008; 15: 40–5.
  15. Elmberg M., Hultcrantz R., Simard J.F. et al. Risk of ischaemic heart disease and cardiomyopathy in patients with haemochromatosis and in their first-degree relatives: A nationwide, population-based study. J Intern Med. 2012; 272 (1): 45–54. DOI: 10.1111/j.1365-2796.2011.02475.x
  16. Bardou-Jacquet E., Morcet J., Manet G. et al. Decreased cardiovascular and extrahepatic cancer-related mortality in treated patients with mild HFE hemochromatosis. J Hepatol. 2015; 62 (3): 682–9. DOI: 10.1016/j.jhep.2014.10.025
  17. Kljaritskaja I.L., Maksimova E.V. Klinicheskie prakticheskie rekomendatsii po vedeniju patsientov s gemohromatozom. Krymskij terapevticheskij zhurnal. 2012; 2: 41–6.
  18. Heilmeyer L., Begemann H. Blut- und Blutkrankheiten: Handbuch der inneren Medizin. Berlin; Gottingen and Heidelberg, 1951; 1149 s.
  19. Lopatkina T.N. v kn. Ruk-vo po gastroenterologii. Pod red. F.I. Komarova, S.I. Rappoporta. M., 2010: 583–7.
  20. Ghilardi R., Piga A., Romeo M.A. et al. Cardiac morbidity and mortality in deferoxamine – or deferiprone-treated patients with thalassemia major. Blood. 2006; 107 (9): 3733–7. DOI: 10.1182/blood-2005-07-2933.
  21. Gaevski P., Martynov A.I., Kokorin V.A. i dr. Vnutrennjaja meditsina osnovannaja na dokazatel'stvah. Pol'sha, Krakov: Prakticheskaja meditsina, 2018; 1680 s.
  22. HFE-Associated Hereditary Hemochromatosis Investigations and Management. British Columbia Medical Association. 2013 April 15; 1–8.
  23. Mershina E.A. i dr. Nekompaktnyj miokard u patsientov s gemohromatozom: fenomen ili kardiopatija? Rol' MRT i molekuljarno-geneticheskih metodov issledovanij v diagnostike. Rossijskij kardiologicheskij zhurnal. 2020; 25 (4): 3759. DOI: 10.15829/1560-4071-2020-3759
  24. Bessmel'tsev S.S., Romanenko N.A. Anemija pri opuholevyh zabolevanijah sistemy krovi. Rukovodstvo dlja vrachej. M.: Izd. IMK, 2017. 286 s.
  25. Romanenko N.A., Gritsaev S.V., Bessmel'tsev S.S. i dr. Effektivnost' eritropoezstimulirujuschih preparatov pri anemii u bol'nyh mielodisplasticheskim sindromom. Gematologija i transfuziologija. 2013; 58 (4): 18–21.
  26. Romanenko N.A., Golovchenko R.A., Bessmel'tsev S.S. i dr. Effektivnost' transfuzij donorskih eritrotsitov u bol'nyh gemoblastozami s anemiej. Transfuziologija. 2015; 16 (2): 29–42.
  27. Natsional'nye klinicheskie rekomendatsii po diagnostike i lecheniju mielodisplasticheskih sindromov vzroslyh. 2018, 60 s.
  28. Gluzman D.F., Skljarenko L.M., Ivanivskaja T.S. i dr. Novoe v klassifikatsii VOZ mieloidnyh novoobrazovanij i ostryh lejkozov (peresmotr 2016 g.). Onkologija. 2016; 18 (3): 184–91.
  29. Kuvshinnikov V.A., Ustinovich A.A., Shenets S.G. i dr. Hronicheskij mielomonotsitarnyj lejkoz (HMML). Meditsinskij zhurnal. 2019; 1: 16–20.
  30. Bolezni peregruzki zhelezom (gemokhromatozy): rukovodstvo dlya vrachei. Pod red. A.G. Rumyantseva, Yu.N. Tokareva. M.: ID Medpraktika-M, 2004; 328 s. (in Russ.).
  31. Ivashkin V.T. Gastroenterologiya. Pod red. V.T. Ivashkina, T.L. Lapinoi. M.: GEOTAR-Media, 2008; 704 s. (in Russ.).
  32. European Association For The Study Of The Liver. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol. 2010; 53 (1): 3–22. DOI: 10.1016/j.jhep.2010.03.001
  33. Bacon B.R., Adams P.C., Kowdley K.V. et al. American Association for the Study of Liver Diseases. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011; 54 (1): 328–43. DOI: 10.1002/hep.24330
  34. Feoktistova E.V. et al. Heart condition in the iron overload syndrome. Prakticheskaya meditsina. 2013; 6 (75): 59–60 (in Russ.).
  35. Peregruzka zhelezom: diagnostika i lechenie. Natsional’nye klinicheskie rekomendatsii, 2018. 14 s. (in Russ.).
  36. Kowdley K.V., Brown K.E., Ahn J. et al. ACG Clinical Guideline: Hereditary Hemochromatosis. Am J Gastroenterol. 2019; 114 (8): 1202–18. DOI: 10.14309/ajg.0000000000000315
  37. Kardiologiya. Natsional’noe rukovodstvo. Pod red. E.V. Shlyakhto. 2-e izd., pererab. i dop. M.: GEOTAR-Media, 2019; 800 s. (in Russ.).
  38. Skvortsov V.V., Gorbach A.N. Changes in the Liver with Hemochromatosis: Symptoms and Diagnostics. Effektivnaya farmakoterapiya. 2020; 16 (1): 74–8 (in Russ.). DOI: 10.33978/2307-3586-2020-16-1-74-78
  39. Hamilton J.P.A. Secondary Iron Overload (Secondary Hemochromatosis). Johns Hopkins University School of Medicine Last full review/revision Sep 2020. Content last modified Sep 2020.
  40. Sisakian H.S., Asatryan B.A., Nanapetyan H.M. Dilated cardiomyopathy: evolution of pathogenesis concepts and potential for new therapies. New Armenian Medical Journal. 2015; 9 (1): 4–18.
  41. 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020; 25 (11): 4083 (in Russ.). DOI: 10.15829/1560-4071-2020-4083
  42. Mekhtiev S.N., Mekhtieva O.A. Iron overload syndrome in chronic hepatic diseases: the focus is on non-alcoholic fat hepatic disease. Lechashchii vrach. 2017; 12: 60–7 (in Russ.).
  43. Isma’eel H., Cappellini M.D., Taher A. Chronic transfusion, iron overload and cardiac dysfunction: a multi-dimensional perspective. Br J Cardiol. 2008; 15: 40–5.
  44. Elmberg M., Hultcrantz R., Simard J.F. et al. Risk of ischaemic heart disease and cardiomyopathy in patients with haemochromatosis and in their first-degree relatives: A nationwide, population-based study. J Intern Med. 2012; 272 (1): 45–54. DOI: 10.1111/j.1365-2796.2011.02475.x
  45. Bardou-Jacquet E., Morcet J., Manet G. et al. Decreased cardiovascular and extrahepatic cancer-related mortality in treated patients with mild HFE hemochromatosis. J Hepatol. 2015; 62 (3): 682–9. DOI: 10.1016/j.jhep.2014.10.025
  46. Klyarytskaya I.L., Maksymova E.V. Clinical practice guidelines for hemochromatosis. Krymskii terapevticheskii zhurnal. 2012; 2: 41–6 (in Russ.).
  47. Heilmeyer L., Begemann H. Blut- und Blutkrankheiten: Handbuch der inneren Medizin. Berlin; Gottingen and Heidelberg, 1951; 1149 s.
  48. Lopatkina T.N. Ruk-vo po gastroenterologii. Pod red. F.I. Komarova, S.I. Rappoporta. M., 2010: 583–7 (in Russ.)].
  49. Ghilardi R., Piga A., Romeo M.A. et al. Cardiac morbidity and mortality in deferoxamine - or deferiprone-treated patients with thalassemia major. Blood. 2006; 107 (9): 3733–7. DOI: 10.1182/blood-2005-07-2933.
  50. Gaevski P., Martynov A.I., Kokorin V.A. et al. Vnutrennyaya meditsina osnovannaya na dokazatel’stvakh. Pol’sha, Krakov: Prakticheskaya meditsina, 2018; 1680 s. (in Russ.).
  51. HFE-Associated Hereditary Hemochromatosis Investigations and Management. British Columbia Medical Association. 2013 April 15; 1–8.
  52. Mershina E.A. et al. The non-compacted myocardium in patients with hemochromatosis: a phenomenon or cardiopathy? The role of magnetic resonance imaging and molecular genetics in diagnosis. Russian Journal of Cardiology. 2020; 25 (4): 3759 (in Russ.). DOI: 10.15829/1560-4071-2020-3759
  53. Bessmel’tsev S.S., Romanenko N.A. Anemiya pri opukholevykh zabolevaniyakh sistemy krovi. Rukovodstvo dlya vrachei. M.: Izd. IMK, 2017. 286 s. (in Russ.).
  54. Romanenko N.A., Gritsaev S.V., Bessmel’tsev S.S. et al. Efficiency of erythropoiesis-stimulating drugs in anemia in patients with the myelodysplastic syndrome. Gematologiya i transfuziologiya. 2013; 58 (4): 18–21 (in Russ.).
  55. Romanenko N.A., Golovchenko R.A., Bessmel’tsev S.S. et al. Efficacy of donor’s red blood cell transfusions in anemic patients with hematological malignancies. Transfuziologiya. 2015; 16 (2): 29–42 (in Russ.).
  56. Natsional’nye klinicheskie rekomendatsii po diagnostike i lecheniyu mielodisplasticheskikh sindromov vzroslykh. 2018, 60 s. (in Russ.).
  57. Gluzman D.F., Sklyarenko L.M., Ivanivskaya T.S. et al. Updated world health organization classification of myeloid neoplasms and acute leukemias (2016 revision). Onkologiya. 2016; 18 (3): 184–91 (in Russ.).
  58. Kouvshinnikov V.A., Ustinovich A.A., Shenez S.G. et al. Chronic myelomonocytic leukemia (CMML). Meditsinskii zhurnal. 2019; 1: 16–20 (in Russ.).